A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02588-y ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Kiyotaka Yoh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-Shi, Chiba, 277-8577, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Exons, Lung Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited.
Abstract (Originalsprache)
Background
Mobocertinib is a novel, synthetic, orally administered tyrosine kinase inhibitor that inhibits many activated forms of epidermal growth factor receptor (EGFR), including those containing exon 20 insertion (ex20ins) mutations. This study aimed to assess the efficacy of mobocertinib in Japanese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR ex20ins mutations.
Methods
This was a phase 2, open-label study. Patients with NSCLC harboring EGFR ex20ins mutations who had not had previous systemic treatment received mobocertinib 160 mg once daily. The primary endpoint was the confirmed objective response rate. A planned interim analysis was completed for the first 14 patients with a centrally confirmed EGFR ex20ins mutation, with enrollment stopped if the number of patients with an objective response was five or fewer.
Results
In total, 33 patients were enrolled into the study (63.6% women; median age: 66 years). At the interim analysis, the objective response rate evaluated by a central independent review committee was 28.6% (4/14, 90% confidence interval: 10.4–54.0); therefore, enrollment was stopped for futility. In the full analysis set, the objective response rate was 18.2% (6/33, 95% confidence interval: 7.0–35.5); of the six responders, one patient (3.0%) had a complete response and five patients (15.2%) had partial responses. The most common treatment-related adverse events were diarrhea, paronychia, stomatitis, and nausea.
Conclusion
Although study enrollment was terminated early owing to futility, our results showed modest activity of mobocertinib in Japanese patients with NSCLC with EGFR ex20ins mutations with no additional safety concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-Shi, Chiba, 277-8577, Japan.
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67, Asahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
- Faculty of Medicine, Department of Medical Oncology, Kindai University, 377-2 Ōnohigashi,, Ōsakasayama-Shi, Ōsaka-Fu, 589-0014, Japan.
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.
- Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi Kiwa, Ube, Yamaguchi, 755-0241, Japan.
- Center for Clinical Oncology, Okayama University Hospital, 2-5-1 Shikata-Cho, Kita-Ku, Okayama, 700-8558, Japan.
Förderung
- Takeda Pharmaceutical Company Limited
Zitieren
APA
Yoh, K., Azuma, K., Hayashi, H., Nishio, M., Chikamori, K., Ichihara, E., Watanabe, Y., Asato, T., Kitagawa, T., Fram, R. J., & Ohe, Y. (2024). A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02588-y
Vancouver
Yoh K, Azuma K, Hayashi H, Nishio M, Chikamori K, Ichihara E, et al. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02588-y
BibTeX
@article{Yoh2024,
author = {Yoh, Kiyotaka and Azuma, Koichi and Hayashi, Hidetoshi and Nishio, Makoto and Chikamori, Kenichi and Ichihara, Eiki and Watanabe, Yasutaka and Asato, Takayuki and Kitagawa, Tadayuki and Fram, Robert J and Ohe, Yuichiro},
title = {A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02588-y}
}
EUVIMED